Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor-T cell therapy with clinically meaningful outcomes demonstrated in patients with relapsed/refractory (r/r) B-cell lymphoma. In a previous pilot study of tisagenlecleucel in r/r follicular lymphoma (FL), 71% of patients achieved a...
Saved in:
| Published in: | Nature Medicine Vol. 28; no. 2; pp. 325 - 332 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Journal Article Magazine Article |
| Language: | English |
| Published: |
New York
Nature Publishing Group US
01.02.2022
Nature Publishing Group |
| Subjects: | |
| ISSN: | 1078-8956, 1546-170X, 1546-170X, 1744-7933 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!